Fighting cancer has just become less expensive for millions of Indian patients. More than 12 years after he electrified the pharma industry by taking on powerful global giants in his quest to supply cheap anti-AIDS drugs, Cipla promoter YK Hamied is back donning the role of a price warrior. This time, his attention is on anti-cancer drugs. On Thursday, Cipla cut prices of key cancer drugs by nearly 75%, an astounding,...
More »SEARCH RESULT
Ranbaxy's finest hour
India joins global drug discovery league The launch by Ranbaxy last week of Synriam, a new drug to treat malaria, is an important milestone. Having made its name by manufacturing generic (off patent) drugs cheaply, India’s pharmaceutical industry has struggled to achieve original drug discovery since the Uruguay Round of trade negotiations signalled the onset of product patents in India. It began to be realised, in time, that there was...
More »Malaria drug, made in India
-The Telegraph An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world's latest drug against malaria, an alternative to standard anti-malarial therapy. India’s Ranbaxy Laboratories today launched the new drug for the treatment of uncomplicated malaria caused by the Plasmodium falciparum parasite, after nine years of research which was partly supported by the Indian government. Clinical trials in India, Tanzania, and Thailand...
More »CCI imposes Rs 317cr fine on 3 firms for collusive bidding
-PTI Competition watchdog CCI has imposed Rs 317 crore in penalties on three companies, including agro-chemicals major United Phosphorus, for collusive bidding to supply ALP tablets to Food Corporation of India (FCI). The aluminium phosphide (ALP) tablet manufacturers -- United Phosphorus, Excel Crop Care, and Sandhya Organics -- have been fined 9 per cent of the their three years' average profits. ALP tablets are used by the FCI for preserving its central pool...
More »A big step forward-CP Chandrasekhar
That this is the first time a compulsory licence has been granted in India is in itself important. INDIA'S long struggle to ensure access to affordable medicines for its people recently took a positive and interesting turn. In early March, just before he demitted office, Controller General of Patents P.H. Kurian passed an order on an application filed by Natco Pharma, headquartered in Hyderabad, requesting a licence to produce an anti-cancer...
More »